María Natalia Gandur Quiroga: The present and future of bispecific antibodies for cancer therapy

María Natalia Gandur Quiroga shared on X:

“‘The present and future of bispecific antibodies for cancer therapy.’

Key findings:

• 14 bispecific antibodies (bsAbs) approved, 11 in oncology
• bsAbs enable unique mechanisms like dual receptor inhibition and immune cell engagement
• New formats: trispecifics, bsAb–drug conjugates and checkpoint inhibitors
• bsAbs in clinical trials are 75% for solid tumors, 25% for blood cancers

 Future directions:

• Next-gen bsAbs (e.g., trispecifics) hold potential for more precise, effective treatments
• Emerging bsAbs target cancer through immune modulation and receptor activation”

The present and future of bispecific antibodies for cancer therapy|Nature Reviews

Authors: Christian Klein, Ulrich Brinkmann, Janice M. Reichert, Roland E. Kontermann

Source: María Natalia Gandur Quiroga/X

More posts featuring María Natalia Gandur Quiroga on oncodaily.com

Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.